Guerbet SA (EPA:GBT)

France flag France · Delayed Price · Currency is EUR
13.36
0.00 (0.00%)
At close: Feb 27, 2026
-49.58%
Market Cap 168.35M
Revenue (ttm) 820.92M
Net Income (ttm) 7.74M
Shares Out 12.60M
EPS (ttm) 0.61
PE Ratio 21.76
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 917
Average Volume 8,827
Open 13.36
Previous Close 13.36
Day's Range 13.32 - 13.40
52-Week Range 11.18 - 28.20
Beta 0.76
RSI 38.63
Earnings Date Mar 11, 2026

About Guerbet

Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate solution; Conray, an iothalamate meglumine injection; Micropaque/Microtrast, a diagnostic imaging interconnected solution; Dotarem, a gadoteric acid-gadoterate meglumine; Elucirem, a macrocyclic gadolinium-based contrast agent; and Artirem, a gadoteric acid that acts a... [Read more]

Industry Medical Devices
Sector Healthcare
Founded 1926
Employees 2,905
Stock Exchange Euronext Paris
Ticker Symbol GBT
Full Company Profile

Financial Performance

In 2024, Guerbet's revenue was 851.12 million, an increase of 6.97% compared to the previous year's 795.65 million. Earnings were 16.08 million, a decrease of -32.61%.

Financial Statements

News

There is no news available yet.